WallStreetZenWallStreetZen

NASDAQ: MXCT
Maxcyte Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MXCT

Based on 1 analyst offering 12 month price targets for Maxcyte Inc.
Min Forecast
$11.00+102.21%
Avg Forecast
$11.00+102.21%
Max Forecast
$11.00+102.21%

Should I buy or sell MXCT stock?

Based on 1 analyst offering ratings for Maxcyte Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MXCT stock forecasts and price targets.

MXCT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
BTIG
Top 21%
80
Strong BuyMaintains$11.00+90.64%2022-08-15Find out why

1 of 1

Forecast return on equity

Is MXCT forecast to generate an efficient return?
Company
-8.42%
Industry
-21.44%
Market
47.84%
MXCT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MXCT forecast to generate an efficient return on assets?
Company
-7.48%
Industry
12%
MXCT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MXCT earnings per share forecast

What is MXCT's earnings per share in the next 2 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.30
Avg 2 year Forecast
-$0.21

MXCT revenue forecast

What is MXCT's revenue in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
$57.6M+37.25%
Avg 2 year Forecast
$77.3M+84.09%
MXCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MXCT revenue growth forecast

How is MXCT forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
37.25%
Industry
5.62%
Market
70.63%
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MXCT vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
MXCT$5.77$11.00+90.64%Strong Buy
SENS$1.20$3.00+150.00%Buy
BNGO$1.87$6.50+247.59%Strong Buy
NVTA$2.62$4.63+76.53%Sell
OABI$4.17$10.25+145.80%Strong Buy
View Top Diagnostic & Research Stocks

Maxcyte Stock Forecast FAQ

Is Maxcyte Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MXCT) stock is to Strong Buy MXCT stock.

Out of 1 analyst, 1 (100%) are recommending MXCT as a Strong Buy, 0 (0%) are recommending MXCT as a Buy, 0 (0%) are recommending MXCT as a Hold, 0 (0%) are recommending MXCT as a Sell, and 0 (0%) are recommending MXCT as a Strong Sell.

If you're new to stock investing, here's how to buy Maxcyte stock.

What is MXCT's earnings growth forecast for 2023-2024?

(NASDAQ: MXCT) Maxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 33.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 84.98%.

Maxcyte's earnings in 2023 is -$23,635,600.On average, 4 Wall Street analysts forecast MXCT's earnings for 2023 to be -$30,614,031, with the lowest MXCT earnings forecast at -$36,736,837, and the highest MXCT earnings forecast at -$24,491,225.

In 2024, MXCT is forecast to generate -$21,429,821 in earnings, with the lowest earnings forecast at -$21,429,821 and the highest earnings forecast at -$21,429,821.

What is MXCT's revenue growth forecast for 2023-2024?

(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 37.25% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.63%.

Maxcyte's revenue in 2023 is $41,989,900.On average, 3 Wall Street analysts forecast MXCT's revenue for 2023 to be $5,881,261,438, with the lowest MXCT revenue forecast at $5,602,367,618, and the highest MXCT revenue forecast at $6,184,034,201.

In 2024, MXCT is forecast to generate $7,888,215,244 in revenue, with the lowest revenue forecast at $7,888,215,244 and the highest revenue forecast at $7,888,215,244.

What is MXCT's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: MXCT) forecast ROA is -7.48%, which is lower than the forecast US Diagnostics & Research industry average of 12%.

What is MXCT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MXCT price target, the average MXCT price target is $11.00, with the highest MXCT stock price forecast at $11.00 and the lowest MXCT stock price forecast at $11.00.

The Wall Street analyst predicted that Maxcyte's share price could reach $11.00 by Aug 15, 2023. The average Maxcyte stock price prediction forecasts a potential upside of 90.64% from the current MXCT share price of $5.77.

What is MXCT's Earnings Per Share (EPS) forecast for 2023-2024?

(NASDAQ: MXCT) Maxcyte's current Earnings Per Share (EPS) is -$0.23. On average, analysts forecast that MXCT's EPS will be -$0.30 for 2023, with the lowest EPS forecast at -$0.36, and the highest EPS forecast at -$0.24. In 2024, MXCT's EPS is forecast to hit -$0.21 (min: -$0.21, max: -$0.21).

What is MXCT's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: MXCT) forecast ROE is -8.42%, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.